Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $45 from $29 and keeps an Equal Weight rating on the shares. Recent data from Ionis’ (IONS) Phase 3 CORE/CORE2 studies of olezarsen in severe hypertriglyceridemia increases the firm’s conviction in the potential of Arrowhead’s plozasiran in SHTG, notes the analyst, who updated the firm’s model ahead of key SHASTA 3/4 data expected in Q3 of 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals Advances Alzheimer’s Treatment with New Clinical Study
- Arrowhead Pharmaceuticals Advances Cholesterol Treatment with Phase 3 Study
- Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study
- Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia
- Arrowhead Pharmaceuticals Advances in SCA2 Treatment with ARO-ATXN2 Study